SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as community members discuss concerns around potential market manipulation and an AI bubble, especially following earnings. Traders are debating whether to buy the dip or prepare for a larger correction, while monitoring key support levels. Some are pointing to macro factors like interest rate expectations and geopolitical concerns as potential catalysts for further volatility.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess its volatile movements amidst optimism in the AI sector. Community discussions revolve around dip-buying strategies and potential profit-taking points, especially with upcoming earnings from key semiconductor players like NVDA. The ongoing government shutdown and concerns about AI valuations add to the uncertainty surrounding this leveraged ETF.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst overall crypto market volatility and the launch of new ETFs, sparking debates on their potential impact. Community discussions revolve around whether XRP can decouple from Bitcoin's influence and the significance of upcoming ISO20022 compliance. Some traders express frustration with price stagnation, while others remain optimistic about long-term utility and institutional adoption.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETF Fundamental Report for XLV

Below is Validea's ETF fundamental report for SPDR Health Care Select Sector SPDR Fund (XLV). The report looks at XLV's exposure to the major investing factors including value, quality, momentum and...

Notable ETF Inflow Detected - XLV, HCA, ELV, COR

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have...

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month 

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.  

<ul class="summary-bullets"><li>Pfizer CEO Albert Bourla made candid remarks on live television regarding the Seagen acquisition and the Metsera deal.</li><li>Seagen, acquired for $43 billion in 2023, is expected to add $10 billion to Pfizer’s risk-adjusted revenue by 2030.</li><li>Bourla said the Metsera deal positions Pfizer to compete more effectively in the obesity drug market against Eli Lilly and Novo Nordisk.</li></ul>Pfizer (PFE) CEO Albert Bourla reportedly dropped the F-bomb on live television while discussing the company’s Seagen acquisition and how lessons learned might influence its outlook on the Metsera (MTSR) deal.Quoting Jim Carmer, Bourla said, “If the whole things fails, then we overpaid. If the whole things succeeds, it’s a f- - -ing good deal.” He added that the deal with Seagen was “transformational” for Pfizer and a driver for its oncology department.On the success of Mastera, he said more data would be needed to determine its success. “Once we get approval, we’ll find out,” Bourla stated.<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> edged 0.4% lower in morning trade, despite strength in the broader market. On Stocktwits, retail sentiment around the company trended in ‘extremely bullish’ territory as chatter dipped to ‘high’ from ‘extremely high’ levels over the past day.<h2 class="st-heading-2">Pfizer’s Seagen Acquisition</h2>Pfizer acquired Seagen, a biotechnology company that specialized in antibody-drug conjugates (ADCs) for cancer therapy, in 2023 for $43 billion. According to the company, the deal is expected to add more than $10 billion to Pfizer’s risk-adjusted revenue by 2030. Pfizer also noted that Seagen nearly doubled the company’s pipeline with 60 programs and added four FDA-approved cancer drugs.&nbsp;<h2 class="st-heading-2">Outlook For Metsera Deal</h2>Bourla stated that the crux of the Metsera deal was that it allows Pfizer to expand its footprint in the “fastest growing market” for obesity drugs. “In our hands, it can create significant value.”He added that the addition of Metsera to Pfizer’s portfolio puts the company in a better position to compete against Eli Lilly (LLY) and Novo Nordisk (NOVO). “All we wanted was the right portfolio, because ours, unfortunately, ours didn’t work,” Bourla told CNBC.He also expects that Pfizer will pay out the full contingent value right (CVR), which grants shareholders additional payments if certain milestones are met with respect to drug development and commercial success.Pfizer won the bidding war for Metsera against Novo Nordisk last week, putting up more than $10 billion to acquire the weight-loss drug startup.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/open-ai-reportedly-exploring-consumer-healthcare-push-with-ai-assistants-and-data-tools/cLPcLr2REcy">OpenAI Reportedly Exploring Consumer Healthcare Push With AI Assistants And Data Tools</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Deals

Quoting Jim Carmer, Pfizer CEO Albert Bourla said, “If the whole things fails, then we overpaid. If the whole things succeeds, it’s a f- - -ing good deal.” 

Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Deals 

Equity

Senate's Deal Signals Potential End to US Govt. Shutdown: Top ETFs to Buy

A bipartisan Senate deal signals an end to the U.S. government shutdown, sparking investor interest in ETFs like XLV and SPY.

<ul class="summary-bullets"><li>Eli Lilly CEO Dave Ricks' comments come after the company reported third-quarter earnings results that topped estimates and hiked its full-year guidance.</li><li>Ricks stated “triple-acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.</li><li>In addition to its injectable therapies, the launch of Orforglipron, a daily oral pill for weight loss, is also in the pipeline.</li></ul>Eli Lilly (LLY) is reportedly looking to expand into pain relief by leveraging the momentum of its weight loss treatments, Mounjaro and Zepbound, which have captured significant share in the fast-growing obesity market.CEO Dave Ricks&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/10/30/watch-cnbcs-full-interview-with-eli-lilly-ceo-dave-ricks.html">told</a> CNBC on Thursday that the company sees potential to move beyond traditional weight management into therapies that address pain associated with obesity. According to the company’s third-quarter earnings report, trials are underway targeting knee and back pain, with a focus on patients who are overweight or have obesity.<blockquote>“We hope to prove that patients who are overweight or have obesity with chronic knee pain find relief with Retatrutide in addition to losing weight.”&nbsp;– Dave Ricks, CEO, Eli Lilly</blockquote>Ricks stated “triple acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.&nbsp; “The first study that we’ll read out for that triple-acting agent will actually be in knee pain,” he said, adding that weight loss drugs have both direct and indirect anti-inflammatory effects.<h2 class="st-heading-2">Eli Lilly Hikes Full-Year Guidance</h2>Ricks’ comments follow the company's upbeat third-quarter (Q3) results and increased full-year guidance, issued earlier on Thursday. The pharmaceutical giant now expects its fiscal 2025 revenue to be between $63 billion and $63.5 billion, up from its previous guidance of $60 billion to $62 billion.<a href="http://stocktwits.com/symbol/LLY">LLY’s stock</a> gained 3.7% in morning trade, with retail sentiment around the pharma giant on Stocktwits improving to ‘bullish’ from ‘bearish’ territory over the past day. Retail chatter increased to ‘high’ from ‘low’ levels.Lilly reported a strong international uptake for its products, rolling out Mounjaro earlier this year in markets including India, China, and Brazil. “We’re seeing global demand for this product,” the CEO said, adding that both Mounjaro and Zepbound have performed well in their early years, signaling the potential for sustained growth in the future.<h2 class="st-heading-2">Oral Pill Expansion</h2>In addition to its injectable therapies, Lilly is preparing to launch Orforglipron, a daily oral pill, which Ricks said has completed Phase 3 trials, with submission expected in Q4. The CEO highlighted that oral therapy meets patient demand for a less intrusive option than weekly injections.&nbsp;He said it also addresses practical barriers in middle-income countries where refrigeration and cold-chain requirements limit access to injectable products. “We think that’s a great spot for Orforglipron,” the CEO noted, adding that the company expects strong global performance for Orforglipron.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-dips-triggers-800-million-in-crypto-liquidations-after-powells-warning/cLGFrJnR3Dy">Bitcoin Dips, Triggers $800 Million In Crypto Liquidations After Powell’s December Warning</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. (Photo by Spencer Platt/Getty Images)

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide 

CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide

UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

<ul class="summary-bullets"><li>Short seller Hunterbrook flagged three new deaths linked to the Dexcom G7 reported in&nbsp;the FDA MAUDE database.</li><li>It stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;</li><li>This is&nbsp;the second time the firm has published data around Dexcom, after first disclosing its short position in September.</li></ul>Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor.<a href="http://stocktwits.com/symbol/DXCM">DXCM’s stock</a> fell nearly 2%, with retail sentiment on Stocktwits around the company trending in ‘bearish’ territory over the past day.&nbsp; Hunterbrook first&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dexcom-stock-slumps-after-hunterbrook-media-investigation-raises-concerns-about-its-g7-device/chD3f5NR3Tm">disclosed</a> its short position in September, citing inaccurate G7 readings that allegedly sent patients to ICUs or&nbsp;led to worse outcomes.&nbsp;<h2 class="st-heading-2">FDA Data Shows Device Risks</h2>The short seller&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom2/">said</a> the new deaths were documented in the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which tracks adverse events involving medical devices. It noted that while the reports do not necessarily prove the device caused the deaths, they help regulators and manufacturers flag potential risks.Hunterbook highlighted that one report described a 69-year-old man whose G7 sensor failed to provide readings, and a second involved a patient using the G7 with an automated insulin pump, whose inaccurate reading may have contributed to fatal ketoacidosis. The third report cited a woman who relied on the G7’s receiver alarms, which had been recalled days earlier for failing to sound properly.<h2 class="st-heading-2">Ongoing Scrutiny And Product Concerns</h2>The short seller stated that at least 13 G7 users have died since the device launched in 2023.&nbsp;It said that even the FDA issued a warning letter to Dexcom in March 2025 following a surprise inspection that revealed unauthorized design changes to a key component, which internal testing found inferior.&nbsp;Dexcom reportedly continued selling the device despite these findings. The short seller stated that the resulting controversy has triggered executive departures, insider selling, and patients returning to older G6 devices or switching to competitors, while ongoing lawsuits and regulatory scrutiny weigh on the company.DXCM’s stock has declined 11% this year and more than 8% since Hunterbrook first disclosed its short position.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-holds-near-114-k-ahead-of-fed-rate-decision-sol-xrp-edge-higher/cLGjgObR3H9">Bitcoin Holds Near $114K Ahead of Fed Rate Decision — SOL, XRP Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Dexcom Shares Slide After Short Seller Flags 3 Additional Deaths From G7 Devices

Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023. 

<ul class="summary-bullets"><li>While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.</li><li>A retail user expected a “well-thought-out earnings call with a road to a bright future, no matter what the numbers say.”</li><li>Stung by the headwinds, UnitedHealth stock is down more than 23% this year.</li></ul>Healthcare services giant UnitedHealth, Inc. (UNH), which has been facing company-specific, macro, and geopolitical challenges, is scheduled to announce its quarterly results before the market opens on Tuesday.Stung by the headwinds,&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth stock</a> is down more than 23% this year.<h2 class="st-heading-2">What Street Expects For UNH’s Q3</h2>According to the Fiscal.ai-compiled consensus estimates, UnitedHealth is expected to report adjusted earnings per share (EPS) of $2.81 and revenue of $113.06 billion. While the consensus EPS estimate suggests a decline from the year-ago’s $3.57, revenue is expected to rise over 12% year-over-year (YoY).In a mid-September note, Morgan Stanley analyst Erin Wright said he came away from an investor dinner with the UNH management team incrementally positive. He noted that the management team, led by CEO Stephen Hemsley, oozed conviction in a turnaround, driven by Medicare Advantage (MA) and Optum Health improvement.Among the headwinds the company faces are higher medical loss ratios that have pressured margins, pricing,&nbsp;as well as operational mistakes in its MA and Affordable Care Act (ACA) businesses.&nbsp;It also faces criminal investigations into the MA billing practices, and the business practices of its&nbsp;Optimum unit, as well as other lawsuits for allegedly improperly denying claims.The company withdrew its full-year 2025 guidance in mid-May, replaced Andrew Witty as CEO with former CEO Hemsley, citing unexpected medical costs and challenges with its Medicare strategy. It, however, reinstated the annual guidance when it released its second-quarter results in late July. The current outlook calls for revenue of $445.5 billion to $448 billion and adjusted EPS of at least $16.<h2 class="st-heading-2">How Retail Is Positioned For Q3 Results</h2>Retail sentiment toward UnitedHealth stock flipped to ‘bullish’ by early Tuesday from ‘bearish’ a day ago. The message volume on the stream has picked up pace to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_28_at_1_35_06_AM_png_d1fda1994a.webp" alt="Screenshot 2025-10-28 at 1.35.06 AM.png" width="623" height="53"><figcaption>UNH sentiment and message volume as of 1:30 a.m ET, Oct. 28 | source: Stocktwits</figcaption></figure>A bullish user looked ahead to better performance after a “kitchen-sink” second quarter.<stembedurl>https://stocktwits.com/newtwo99/message/633929931</stembedurl>Another user expected a “well-thought-out earnings call with a road to a bright future no matter what the numbers say.” If the numbers come in better than expected, they see it as an added advantage.<stembedurl>https://stocktwits.com/PhoenixRisingMD/message/633928829</stembedurl><h2 class="st-heading-2">Wall Street Lift Price Targets Ahead Of Q3 Print</h2>Since the start of October, UnitedHealth’s stock has received a string of price target hikes, with the updated price targets ranging from $335 to $433, according to the Fly. While lifting its price target to $409 from $317 earlier this month, Jefferies analyst David Windley said he sees upside for MA margins in 2026, thanks to assertive group repricing efforts. The analyst has a ‘Buy’ rating on the stock.Goldman Sachs initiated coverage of the UnitedHealth stock with a ‘Buy rating’ and $406 price target. While the firm believes that the managed care industry faces its most significant underwriting downturn in over 15 years, it recommended increased exposure to MA, factoring in a margin recovery phase beginning in 2026.&nbsp;After bumping up the price target to $430 from $300, Mizuho, which has an ‘Overweight’ rating, noted increased earnings visibility on key issues and rotation into the healthcare sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nxp-semiconductor-stock-rose-in-today-s-after-hours/cLGjTBXR3ur">Why NXP Semiconductor Stock Rose In Today’s After-hours</a>

In this photo illustration, a smartphone displays the logo of UnitedHealth Group Incorporated. (Photo illustration by Cheng Xin/Getty Images)

UnitedHealth Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

While the consensus EPS estimate suggests a decline from a year ago, revenue is expected to rise by more than 12% year over year.

UnitedHealth (UNH) Stock In Spotlight Ahead Of Earnings: Retail Traders Bet On Recovery After ‘Kitchen-Sink’ Q2

4 Sector ETFs & Stocks to Gain Despite Lower-Than -Expected Inflation

September records lower-than-expected inflation! Energy (OIH), Restaurants (EATZ), Healthcare (XLV) and Transportation (XTN) ETFs may still shine in the near term.

XLV
Health Care Select Sector SPDR Fund

Feed

News

Sentiment

Fundamentals

Info

Latest XLV News

XLVHealth Care Select Sector SPDR Fund